Phase 2 RCT in 359 adults with acute schizophrenia: LB-102 50 mg and 75 mg reduced PANSS total score at week 4 more than placebo (-14.3 and -14.0 vs -9.3); 100 mg was nominally significant. Adverse events were 69%, 57% and 75% vs 56% with placebo.
RCTn = 359
Eramo et al. Antipsychotic Efficacy and Safety of LB-102 in the Treatment of Adults With Acute Schizophrenia: A Randomized Clinical Trial